2型糖尿病和动脉粥样硬化性心血管疾病患者不良事件报告中捕获的心力衰竭结局：来自VERTIS CV试验的观察结果

IF 16.9 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

European Journal of Heart Failure Pub Date : 2025-01-10 DOI:10.1002/ejhf.3511

Ambarish Pandey, Ahmed A. Kolkailah, Darren K. McGuire, Robert C. Frederich, Nilo B. Cater, Francesco Cosentino, Richard E. Pratley, Samuel Dagogo-Jack, David Z.I. Cherney, Willy Wynant, Ira Gantz, James P. Mancuso, Urszula Masiukiewicz, Christopher P. Cannon

{"title":"2型糖尿病和动脉粥样硬化性心血管疾病患者不良事件报告中捕获的心力衰竭结局：来自VERTIS CV试验的观察结果","authors":"Ambarish Pandey, Ahmed A. Kolkailah, Darren K. McGuire, Robert C. Frederich, Nilo B. Cater, Francesco Cosentino, Richard E. Pratley, Samuel Dagogo-Jack, David Z.I. Cherney, Willy Wynant, Ira Gantz, James P. Mancuso, Urszula Masiukiewicz, Christopher P. Cannon","doi":"10.1002/ejhf.3511","DOIUrl":null,"url":null,"abstract":"In VERTIS CV, ertugliflozin was associated with a 30% risk reduction for adjudication-confirmed, first and total hospitalizations for heart failure (HHF) in participants with type 2 diabetes and atherosclerotic cardiovascular disease. We evaluated the impact of ertugliflozin on the broader spectrum of all reported heart failure (HF) events independent of adjudication confirmation.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"20 1","pages":""},"PeriodicalIF":16.9000,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial\",\"authors\":\"Ambarish Pandey, Ahmed A. Kolkailah, Darren K. McGuire, Robert C. Frederich, Nilo B. Cater, Francesco Cosentino, Richard E. Pratley, Samuel Dagogo-Jack, David Z.I. Cherney, Willy Wynant, Ira Gantz, James P. Mancuso, Urszula Masiukiewicz, Christopher P. Cannon\",\"doi\":\"10.1002/ejhf.3511\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In VERTIS CV, ertugliflozin was associated with a 30% risk reduction for adjudication-confirmed, first and total hospitalizations for heart failure (HHF) in participants with type 2 diabetes and atherosclerotic cardiovascular disease. We evaluated the impact of ertugliflozin on the broader spectrum of all reported heart failure (HF) events independent of adjudication confirmation.\",\"PeriodicalId\":164,\"journal\":{\"name\":\"European Journal of Heart Failure\",\"volume\":\"20 1\",\"pages\":\"\"},\"PeriodicalIF\":16.9000,\"publicationDate\":\"2025-01-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Heart Failure\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ejhf.3511\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ejhf.3511","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

在VERTIS CV中，厄图列净与2型糖尿病和动脉粥样硬化性心血管疾病参与者因心力衰竭（HHF）首次住院和总住院的风险降低30%相关。我们评估了厄图列净对所有报告的心力衰竭（HF）事件的更广泛的影响，独立于裁决确认。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial

In VERTIS CV, ertugliflozin was associated with a 30% risk reduction for adjudication-confirmed, first and total hospitalizations for heart failure (HHF) in participants with type 2 diabetes and atherosclerotic cardiovascular disease. We evaluated the impact of ertugliflozin on the broader spectrum of all reported heart failure (HF) events independent of adjudication confirmation.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Journal of Heart Failure 医学-心血管系统

CiteScore

27.30

自引率

11.50%

发文量

365

审稿时长

1 months

期刊介绍： European Journal of Heart Failure is an international journal dedicated to advancing knowledge in the field of heart failure management. The journal publishes reviews and editorials aimed at improving understanding, prevention, investigation, and treatment of heart failure. It covers various disciplines such as molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, clinical sciences, social sciences, and population sciences. The journal welcomes submissions of manuscripts on basic, clinical, and population sciences, as well as original contributions on nursing, care of the elderly, primary care, health economics, and other related specialist fields. It is published monthly and has a readership that includes cardiologists, emergency room physicians, intensivists, internists, general physicians, cardiac nurses, diabetologists, epidemiologists, basic scientists focusing on cardiovascular research, and those working in rehabilitation. The journal is abstracted and indexed in various databases such as Academic Search, Embase, MEDLINE/PubMed, and Science Citation Index.